SCHEMBL4477367

SCHEMBL4477367

Cc1ccc(C)c(-c2ccc(C(=O)N3CCOC(c4ccccc4)C3)cc2)c1

nearest known ligand 0.51

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.51
PDE2A O00408 7/20 0.49
NAMPT P43490 1/20 0.44
MAPK14 Q16539 1/20 0.41
USP30 Q70CQ3 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
ATM Q13315 1/20 0.41
POLB P06746 1/20 0.41
HTT P42858 1/20 0.41
CREBBP Q92793 1/20 0.40
GHSR Q92847 1/20 0.40
SLC6A7 Q99884 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4462669 0.81 CNR2 (0.60) CNR2PDE2ANAMPTUSP30NPC1
SCHEMBL4472712 0.78 CNR2 (0.61) CNR2PDE2ANAMPTUSP30NPC1
SCHEMBL4465522 0.78 CNR2 (0.62) CNR2PDE2ANAMPTUSP30NPC1
SCHEMBL4489016 0.77 NPC1 (0.49) PDE2ANAMPTUSP30NPC1RAB9A
SCHEMBL1710753 0.77 USP30 (0.50) PDE2ANAMPTUSP30NPC1RAB9A
SCHEMBL4474086 0.77 CNR2 (0.82) CNR2
SCHEMBL12345132 0.74 MAPK14 (0.62) CNR2MAPK14NPC1RAB9AATM
SCHEMBL4699677 0.73 CNR2 (0.48) CNR2PDE2ANAMPTUSP30
SCHEMBL25453440 0.71 USP30 (0.54) CNR2PDE2AUSP30ATMPOLB
SCHEMBL19049384 0.71 USP30 (0.54) CNR2PDE2AUSP30ATMPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595397-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-29 US disclosed
US-7595397-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-29 US disclosed
US-7595397-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-29 US disclosed
EP-1966132-A2 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-09-10 EP disclosed
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-16 US disclosed
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-16 US disclosed
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-16 US disclosed
WO-2007070760-A2 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-06-21 WO disclosed
WO-2007070760-A2 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor CNR1, CNR2, ARRB1 CNR2 2/4885PDE2A 897/4885NAMPT 3796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.